NYSEMKT: APUSApimeds Pharmaceuticals Us Inc Stock
$1.93+0.15 (+8.43%)
Updated Sep 26, 2025
APUS Price
$1.93
Fair Value Price
N/A
Market Cap
$24.27M
52 Week Low
$1.37
52 Week High
$4.00
P/E
-5x
P/B
2.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$4M
Beta
-0.42
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APUS's potential to beat the market
- APUS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
APUS
RankedUnranked of 59
RankedUnranked of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.75 | A | |
| $38.81 | A | |
| $23.92 | A |
Be the first to know about important APUS news, forecast changes, insider trades & much more!
APUS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APUS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APUS is poor value based on its book value relative to its share price (2.49x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.19x)
P/B vs Industry Valuation
APUS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APUS due diligence checks available for Premium users.
Valuation
APUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5x
Industry
-26.18x
Market
36.62x
APUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.49x
Industry
2.19x
APUS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APUS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
APUS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.5M
Liabilities
$809.0k
Debt to equity
0.08
APUS's short-term assets ($10.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APUS's short-term assets ($10.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$13.4k
Financing
$11.9M
APUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APUS vs Pharmaceutical Stocks
Apimeds Pharmaceuticals Us Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.